InsiderTrades.com logo
Joris Wilms net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joris Wilms Biography and Net Worth

COO of Y-mAbs Therapeutics

Joris Wilms, serves as SVP, Chief Operating Officer. Joris Wilms has extensive industry experience in Clinical Development primarily within oncology and hematology indications. He has been responsible for overseeing several first-in-human studies and pivotal clinical trials, leading to the approval of two monoclonal antibodies. Previous positions include VP Clinical Trial Services and Pharmacovigilance at KLIFO A/S, and Associate Director Clinical Development at Genmab A/S. Joris Wilms received his MSc Pharm from the University of Groningen, Netherlands.

What is Joris Wilms' net worth?

The estimated net worth of Joris Wilms is at least $263.47 thousand as of August 26th, 2024. Mr. Wilms owns 30,600 shares of Y-mAbs Therapeutics stock worth more than $263,466 as of April 30th. This net worth estimate does not reflect any other investments that Mr. Wilms may own. Learn More about Joris Wilms' net worth.

How do I contact Joris Wilms?

The corporate mailing address for Mr. Wilms and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Joris Wilms' contact information.

Has Joris Wilms been buying or selling shares of Y-mAbs Therapeutics?

Joris Wilms has not been actively trading shares of Y-mAbs Therapeutics within the last three months. Most recently, Joris Wilms sold 5,000 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a transaction totalling $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares of the company's stock, valued at $449,514. Learn More on Joris Wilms' trading history.

Who are Y-mAbs Therapeutics' active insiders?

Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), Michael Rossi (CEO), Johan Wedell-Wedellsborg (Director), and Joris Wilms (COO). Learn More on Y-mAbs Therapeutics' active insiders.

Joris Wilms Insider Trading History at Y-mAbs Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2024Sell5,000$14.69$73,450.0030,600View SEC Filing Icon  
See Full Table

Joris Wilms Buying and Selling Activity at Y-mAbs Therapeutics

This chart shows Joris Wilms's buying and selling at Y-mAbs Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $8.61
Low: $8.61
High: $8.61

50 Day Range

MA: $8.58
Low: $8.51
High: $8.61

2 Week Range

Now: $8.61
Low: $3.55
High: $8.61

Volume

N/A

Average Volume

637,200 shs

Market Capitalization

$391.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54